| Bioactivity | PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. PARP-1/Proteasome-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis[1]. |
| Target | PARP-1, Proteasome |
| Name | PARP-1/Proteasome-IN-1 |
| Formula | C36H46BFN4O5S |
| Molar Mass | 676.65 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. He H et al. Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer[J]. European Journal of Medicinal Chemistry, 2023: 115943. |
PARP-1/Proteasome-IN-1
CAS: F: C36H46BFN4O5S W: 676.65
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on b
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.